Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

百奧賽圖(北京)醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2315)

POLL RESULTS OF THE 2025 ANNUAL GENERAL MEETING HELD ON MAY 21, 2026

References are made to the notice (the "**Notice**") and the circular (the "**Circular**") of the AGM both dated April 23, 2026 of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (the "**Company**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as those defined in the Notice and the Circular.

The AGM was held with the combination of a physical meeting at the conference room of 12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, PRC and a virtual meeting online on Thursday, May 21, 2026 at 2:00 p.m.. The AGM was held in accordance with the requirements of the PRC Company Law and the Articles.

As at the date of the AGM, the total number of issued shares of the Company was 446,898,420 (excluding Treasury Shares, if any), including 110,781,920 H Shares and 336,116,500 A Shares, all of which entitled the Shareholders to attend the AGM and vote for or against or abstain from voting on the resolutions (the "**Resolutions**") proposed at the AGM. The Company did not hold treasury shares and no voting rights of treasury shares has been exercised at the AGM. The trustees of the share award scheme of the Company holds an aggregate of 3,432,358 unvested Shares (comprising (i) the underlying Shares of the granted share awards which remain unvested; and (ii) such other Shares held for future grant of share awards) with voting rights attached (representing approximately 0.77% of the number of the issued Shares) had abstained from voting on any of the resolutions at the AGM. A total of 840 Shareholders and their proxies holding an aggregate of 332,796,065 voting Shares, representing approximately 74.47% of the total number of voting Shares, attended the AGM. Dr. Shen Yuelei, the chairman of the Company, acted as the chairman of the AGM and presided over it. All the Directors, the senior management of the Company, as well as the secretary of the Board were present at the meeting either in person or by means of telecommunication.

Pursuant to the Listing Rules and as advised by the Company's PRC legal advisors, Dr. Shen Yuelei and Dr. Ni Jian and their controlled corporations (Note 1), collectively holding 14,063,800 H Shares and 93,240,540 A Shares, were required to, and had abstained from voting on the resolution numbered 5 at the AGM. In addition, (i) State Development & Investment Group Co., Ltd. ("**SDIC**") and its controlled corporations (Note 2), collectively holding 72,937,440 A Shares; (ii) China Merchants Bank Co., Ltd. ("**CMBC**") and its controlled corporations (Note 3), collectively holding 14,912,544 H Shares and 51,171,840 A Shares; (iii) China Life Chengda (Shanghai) Healthcare Equity Investment Management Company Limited, holding 14,296,320 A Shares; (iv) Jiangsu Jiequan Chengdai Equity Investment Center (Limited Partnership), holding 9,222,840 A Shares; (v) PICC Beijing Health Care Fund, L.P., holding 9,222,840 A Shares; (vi) Shenzhen Zhaoyin Gongying Equity Investment Partnership (Limited Partnership), holding 1,355,760 A Shares; (vii) Zhuhai Growth Win-Win Venture Capital Fund (Limited Partnership), holding 2,459,520 A Shares are investors of a related party contemplated under the resolution numbered 5, such parties had abstained from voting on the resolution numbered 5 at the AGM as advised by the Company's PRC legal advisors. Accordingly, the total number of Shares entitling the Shareholders to attend and vote on the resolution numbered 5 and other resolutions proposed at the AGM were 164,014,976 and 446,898,420 respectively. The total number of Shares with voting rights, on the resolution numbered 5 and other resolutions, represented by the Shareholders attending the AGM in person or by proxy were 53,727,901 and 332,796,065 representing approximately 32.76% and 74.47% of the total number of Shares with voting rights, respectively.

Save as disclosed above, to the best of the Directors' knowledge, information and belief, no Shareholders were required to abstain from voting on any of the Resolutions in accordance with the requirements of the Listing Rules. There were no Shares entitling the holder(s) to attend the AGM but abstain from voting in favour of any of the Resolutions under rule 13.40 of the Listing Rules. None of the Shareholders had stated his/her/its intention to vote against or to abstain from voting on any of the Resolutions. The Company was not aware of any Shareholders indicating their intention to vote against any of the Resolutions or abstain from voting at the AGM. All Resolutions were put to vote by way of poll.

Note 1: Shanghai Baiao Evergreen Technology Development Center (Limited Partnership)* (上海百奧常青科技發展中心(有限合夥)), Beijing Baiao Changsheng Technology Development Center (Limited Partnership)* (北京百奧常盛科技發展中心(有限合夥)), Beijing Eucure Evergreen Technology Development Center (Limited Partnership)* (北京祐和常青科技發展中心(有限合夥)) and Shanghai Eucure Changsheng Technology Development Center (Limited Partnership)* (上海祐和常盛科技發展中心(有限合夥)).

Note 2: State Development & Investment Corporation (SDIC) VC Fund (Ningbo) of Technology Transfer and Commercialization (Limited Partnership), State Development & Investment Corporation (SDIC) VC Fund (Shanghai) of Technology Transfer and Commercialization (Limited Partnership) and State Development & Investment Corporation (SDIC) Gaoxin (Shenzhen) VC Fund (Limited Partnership).

Note 3: Astral Eminent Limited, Zhaoyin Chengzhang Qihao Investment (Shenzhen) Partnership (Limited Partnership) (招銀成長柒號投資(深圳)合夥企業(有限合夥)), Shenzhen Zhaoyin Langyao Growth Equity Investment Fund Partnership (L.P.) (深圳市招銀朗曜成長股權投資基金合夥企業(有限合夥)), Zhaoyin Chengzhang Shijiuhao Equity Investment Fund Partnership (Limited Partnership) (深圳市招銀成長拾玖號股權投資基金合夥企業(有限合夥)) and CMB International Capital Management (Shenzhen) Co., Ltd. (招銀國際資本管理(深圳)有限公司).

Tricor Investor Services Limited, the Company's H share registrar, two representatives from the Company's Shareholders and a lawyer from Zhong Lun Law Firm, were responsible for vote counting and acted as the scrutineer thereof. The poll results in respect of the Resolutions proposed at the AGM were as follows:

ORDINARY RESOLUTIONS		**No. of Votes (%)**		
		For	**Against**	**Abstain**
1.	To consider and approve the work report of the Board for 2025	332,710,846 (99.9744%)	20,096 (0.0060%)	65,123 (0.0196%)
2.	To consider and approve the proposed re-appointment of KPMG, Certified Public Accountants as the auditor of the Company for 2026 and authorize the Board to fix its remuneration	332,699,977 (99.9711%)	30,965 (0.0093%)	65,123 (0.0196%)
3.	To consider and approve the proposed remuneration (allowances) of Directors for 2026	332,700,174 (99.9712%)	29,268 (0.0088%)	66,623 (0.0200%)
4.	To consider and approve the proposed 2025 profit distribution plan	332,728,689 (99.9798%)	753 (0.0002%)	66,623 (0.0200%)
5.	To consider and approve confirmation of the Company's daily related party transactions in 2025 and estimated daily related party transactions in 2026	53,646,682 (99.8488%)	20,096 (0.0374%)	61,123 (0.1138%)
SPECIAL RESOLUTIONS				
6.	To consider and approve the proposed application for comprehensive credit facilities and provision of guarantee for the Company and subsidiaries	332,284,258 (99.8462%)	446,684 (0.1342%)	65,123 (0.0196%)
7.	To consider and approve the proposed change of registered capital of the Company and the amendments to the Articles of Association	332,710,846 (99.9744%)	20,096 (0.0060%)	65,123 (0.0196%)

As more than 50% of votes were casted in favour of each of the above ordinary resolutions numbered 1 to 5, and more than two-thirds of votes were casted in favour of each of the above special resolutions numbered 6 to 7, all of the above Resolutions were duly passed at the AGM.

WITNESS BY LAWYERS

Zhong Lun Law Firm, the Company's PRC legal adviser, considers that the convening and holding procedures of the AGM complied with the relevant requirements of the Company Law of the People's Republic of China, the Securities Law of the People's Republic of China, the Rules for General Meetings of Listed Companies and other laws, regulations and normative documents and the Articles of Association. The qualifications of the attendees and the convener of the meeting were legal and valid, and the voting procedures and voting results of the meeting were legal and valid.

AMENDMENTS TO THE ARTICLES OF ASSOCIATION

The amended Articles of Association duly passed by the Shareholders at the AGM take effect from May 21, 2026. The full text of the amended Articles of Association is available for download at the website of the Hong Kong Stock Exchange (www.hkexnews.hk) and the Company's website (https://biocytogen.com.cn).

By order of the Board
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Shen Yuelei
Chairman of the Board, Chief Executive Officer and Executive Director

Hong Kong, May 21, 2026

As at the date of this announcement, the Board comprises Dr. Shen Yuelei as chairman, chief executive officer and executive Director, Dr. Ni Jian as executive Director; Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang as non-executive Directors; Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan as independent non-executive Directors; and Ms. Li Yan as employee Director.